natgillin/translations-raw huggingface dataset:
to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at risk of long-term, severe neutropenia;
za skrajšanje trajanja nevtropenije pri bolnikih, ki prejemajo zdravljenje za uničenje celic kostnega mozga pred njegovo presaditvijo (kot npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dolgotrajno, hudo obliko nevtropenije;
to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at risk of long-term, severe neutropenia;
za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dalj časa trajajočo hudo nevtropenijo;
to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at risk of long-term, severe neutropenia; to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
za skrajšanje trajanja nevtropenije pri bolnikih, ki prejemajo zdravljenje za uničenje celic kostnega mozga pred njegovo presaditvijo (kot npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dolgotrajno, hudo obliko nevtropenije; za povišanje ravni nevtrofilcev in zmanjšanje tveganja okužb pri bolnikih z nevtropenijo z anamnezo hudih, ponavljajočih se okužb;
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration.
Da zmanjšamo incidenco in resnost kožnih reakcij, dajemo kortikosteroid dan pred dajanjem pemetrekseda, na dan dajanja pemetrekseda in naslednji dan.
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration.
Za zmanjšanje incidence in resnosti kožnih reakcij, dajemo kortikosteroid dan pred dajanjem pemetrekseda, na dan dajanja pemetrekseda in naslednji dan.
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration.
Za zmanjšanje incidence in resnosti kožnih reakcij, se daje kortikosteroid dan pred dajanjem pemetrekseda, na dan dajanja pemetrekseda in naslednji dan.
To reduce the potential impact of visual disturbances take the tablets before going to bed (see also section 3).
Da zmanjšate možen vpliv težav z vidom, zaužijte zdravilo Ketek pred spanjem (glejte tudi poglavje 3).
To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban.
Za zmanjšanje potencialnega tveganja za krvavitev povezanega z nevraksialno (epiduralno/spinalno) anestezijo ali spinalno punkcijo in sočasno uporabo rivaroksabana, je treba upoštevati farmakokinetični profil rivaroksabana.
To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban.
Za zmanjšanje potencialnega tveganja za krvavitev, povezanega z nevraksialno (epiduralno/spinalno) anestezijo ali spinalno punkcijo in sočasno uporabo rivaroksabana, je treba upoštevati farmakokinetični profil rivaroksabana.
To reduce the rate of infection, it may be necessary to increase the dosage and aim for higher trough levels.
Da bi zmanjšali pogostnost okužb, bo morda potrebno povečati odmerek, da bi dosegli višje ravni.
To reduce the rate of infection, it may be necessary to increase the dose and aim for higher trough levels.
Za zmanjšanje pojavnosti okužb bo morda potreben večji odmerek, da se dosežejo višje vrednosti najnižje koncentracije.
To reduce the risk of accidental needle injury, never replace the inner needle cap.
Da boste zmanjšali tveganje za poškodbo z iglo, nikdar ne namestite nazaj notranjega pokrovčka igle.
To reduce the risk of getting injection site reaction you must:
Za zmanjšanje tveganj reakcij na mestu injiciranja
To reduce the risk of getting injection site reaction you must:
Za zmanjšanje tveganj reakcij na mestu injiciranja:
To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving Soliris unless the risk of delaying Soliris therapy outweigh the risks of developing a meningococcal infection.
Za zmanjšanje tveganja okužbe morajo biti vsi bolniki cepljeni najmanj 2 tedna pred pričetkom prejemanja zdravila Soliris, razen če tveganje odložitve zdravljenja z zdravilom Soliris odtehta tveganja razvoja meningokokne okužbe.
To reduce the risk of infection, it is important that you follow the instructions provided in Section 7.
Pomembno je, da se ravnate po navodilih v poglavju 7, ker s tem zmanjšate tveganje za okužbo.
To reduce the risk of infusion-related reactions, patients may be given other medicines before or during treatment with Remsima or the infusion time may be slowed down.
Za zmanjšanje tveganja za pojav reakcij, povezanih z infundiranjem, lahko bolniki pred ali med zdravljenjem z zdravilom Remsima prejmejo druga zdravila ali pa se upočasni hitrost infundiranja.
To reduce the risk of liver injury you should not use Tasmar if
Da bi zmanjšali tveganje za poškodbo jeter, zdravila Tasmar ne smete jemati
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment.
Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo ABASAGLAR enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v prvih tednih zdravljenja zmanjšati za 20 do 30%.
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Bolniki, ki z insulina NPH dvakrat na dan prehajajo na zdravilo Lantus enkrat na dan, morajo za zmanjšanje nevarnosti nočne ali zgodnje jutranje hipoglikemije v prvih tednih zdravljenja z zdravilom Lantus zmanjšati dnevni odmerek bazalnega insulina za 20 do 30%.
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Toujeo should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo Toujeo enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v prvih tednih zdravljenja z zdravilom Toujeo zmanjšati za 20 do 30%.
To reduce the risk of OHSS, ultrasonographic assessments of follicular development should be performed prior to treatment and at regular intervals during treatment.
Za zmanjšanje tveganja za nastanek OHSS je treba opraviti ultrazvočno oceno razvoja foliklov pred zdravljenjem in v rednih časovnih razmikih med zdravljenjem.
To reduce the risk of unexpected needle sticks, never put the inner needle cap back on when you have removed it from the needle.
Da boste zmanjšali tveganje za nenamerne vbode z iglo, nanjo nikdar znova ne nameščajte notranjega pokrovčka igle, ki ste ga že sneli.
To reduce the risk of unexpected needle sticks, never put the inner needle cap back on when you have removed it from the needle.
Da boste zmanjšali tveganje za neželene vbode z iglo, nanjo nikdar znova ne nameščajte notranjega pokrovčka igle, ki ste ga že sneli.
To reduce the systemic absorption, see 4.2.
Glede zmanjšanja sistemske absorpcije zdravila glejte poglavje 4.2.
To reduce the systemic absorption, see section 4.2.
Glede zmanjšanja sistemske absorpcije zdravila glejte poglavje 4.2.
To reduce the systemic absorption, see section 4.2.
Za zmanjšanje sistemske absorbcije glejte poglavje 4.2.
To reduce this risk, patients receiving LEMTRADA should avoid ingestion of uncooked or undercooked meats, soft cheeses and unpasteurized dairy products for at least one month after LEMTRADA treatment.
Za zmanjšanje tega tveganja se morajo bolniki, ki prejemajo zdravilo LEMTRADA, vsaj še mesec dni po zdravljenju izogibati uživanju nekuhanega ali premalo kuhanega mesa, mehkim sirom in izdelkom iz nepasteriziranega mleka.
To reduce this risk, you should avoid ingestion of uncooked or undercooked meats, soft cheeses and unpasteurized dairy products for at least one month after LEMTRADA treatment.
Da zmanjšate to tveganje, se vsaj mesec dni po zdravljenju z zdravilom LEMTRADA izogibajte uživanju nekuhanega ali premalo kuhanega mesa, mehkim sirom in izdelkom iz nepasteriziranega mleka.
To refer to the Ranexa package leaflet for more information.
Bolnik lahko več informacij najde v navodilu za uporabo zdravila Ranexa.
To refer to the Ranexa SPC prior to prescribing any medications to the patient, as there are potential drug interactions which should be taken into consideration.
Navodilo, naj pred predpisovanjem katerega koli zdravila bolniku preberejo povzetek glavnih značilnosti zdravila Ranexa, saj obstajajo interakcije z drugimi zdravili, ki jih je treba upoštevati.
To remind female patients to tell their doctor if breastfeeding
opomnik za ženske, da svojega zdravnika obvestijo, če dojijo;
To remind patients to show the Patient Education Card to Doctors/HCPs involved with their medical care (especially in the event of medical emergencies and/or if new Doctors/HCPs are involved.)
Spomniti bolnike, da zdravnikom / zdravstvenim delavcem, ki jih zdravijo (zlasti v nujnih primerih in /ali kadar so vključeni novi zdravniki / zdravstveni delavci) pokažejo Izobraževlno kartico za bolnike.
To remove a large air bubble:
Velik zračni mehurček odstranite tako:
To remove a tablet from the blister the following sequence should be carried out;
Za odstranitev tablete iz pretisnega omota upoštevajte naslednje zaporedje:
To remove air bubbles from the pre- filled syringe, hold the syringe with the needle pointing up.
Držite injekcijsko brizgo z iglo obrnjeno navzgor, da boste odstranili zra ne mehur ke iz injekcijske brizge.
To remove air bubbles from the syringe, hold the syringe with the needle pointing up.
Injekcijsko brizgo držite pokončno, igla naj bo obrnjena navzgor, da boste lahko odstranili zračne mehurčke.
To remove air bubbles, gently flick the syringe until all the air collects at the top - then slowly push the plunger in until the air bubbles are gone.
Da odstranite mehurčke, s prsti nežno udarjajte po brizgi, da se vsi mehurčki zberejo na vrhu - nato počasi potiskajte bat, dokler vsi mehurčki ne izginejo.
To remove air, point the syringe needle upwards.
Da odstranite zrak, usmerite iglo injekcijske brizge navzgor.
To remove any bubbles, the syringe should be tapped gently.
Da odstranite mehurčke, nežno potrkajte po injekcijski brizgi.
To remove capsule push through from this side Fold and reclose after removing capsule
Za odstranitev kapsule pritisnite s te strani.
To remove the clear plastic cap: push towards the syringe and then pull the cap off.
Prozoren plastični pokrov odstranite tako, da: ga potisnete proti injekcijski brizgi in ga nato snamete z igle.
To remove the clear plastic cap: push towards the syringe and then pull the cap off.
Prozoren plastični pokrov odstranite tako, da: ga potisnite proti injekcijski brizgi in nato pokrov snamete.
To remove the syringe from the package, hold it by its body as indicated by the arrows in the tray.
Pri odstranjevanju injekcijske brizge iz ovojnine jo primite za njeno telo, kot je označeno s puščicami na podstavku.
To report all cases of pregnancy occurring during therapy.
Prijaviti je treba vse primere nosečnosti, do katerih pride med zdravljenjem.
To report any onset of a limp or complaint of hip or knee pain to their physician so it can be evaluated.
Navodila za poročanje zdravniku o pojavu šepanja ali bolečinah v kolku ali kolenu, da bi bilo mogoče stanje oceniti.
To report the onset of severe headache, blurred vision and associated nausea and vomiting to their physician.
Navodila za poročanje zdravniku o pojavu hudega glavobola, zamegljenega vida in s tem povezane slabosti ter bruhanja.
To reset the FORSTEO, follow the steps below.
Za ponovno nastavitev injekcijskega peresnika FORSTEO, sledite spodnjim korakom.
To return to see their physician approximately 24 – 72 hours after injection for an examination of the injected hand and a finger extension procedure to disrupt the cord.
naj pridejo na kontrolo k svojemu zdravniku približno 24 – 72 ur po injiciranju da jim bo
To return unused capsules at the end of the treatment (disposal will depend on local requirements)
Vrniti neporabljene kapsule po zaključku zdravljenja (odstranjevanje zdravila bo odvisno od lokalnih zahtev).
To revaccinate, a booster injection should be given at 6-month intervals.
Za revakcinacijo je treba poživitvene injekcije dajati v 6- mesečnih presledkih.
To see if your BMI is 28 or above, find your height on the chart.
Da bi preverili, ali je vaš ITM enak ali večji od 28, v tabeli poiščite svojo višino.
To see precisely how much insulin is left use the dose counter:
Če želite videti, koliko insulina je še ostalo, uporabite števec odmerka:
To see precisely how much insulin is left, use the dose counter:
Če želite natančno videti, koliko insulina je še ostalo, uporabite števec odmerka:
To see precisely how much insulin is left, use the dose counter: Turn the dose selector until the dose counter stops.
Če želite videti, koliko je še insulina, uporabite števec odmerka: Vrtite izbirnik odmerka, dokler se števec odmerka ne ustavi.
To see precisely how much solution is left, use the dose counter: Turn the dose selector until the dose counter stops.
Zavrtite števec odmerka dokler se števec odmerka ne ustavi.
To set the correct dose, turn the cap as many times as indicated as follows:
Pravilen odmerek nastavite tako, da obrnete pokrovček tolikokrat, kot je navedeno:
To setup the pen dial the dose.
Nastavite odmerek na peresniku.
To start a dose, press and release the dosing button 2 times within 3 seconds.
Dovajanje odmerka sprožite tako, da pritisnete in spustite gumb za odmerjanje dvakrat v 3 sekundah.
To stay within your daily allowance for fat, snacks should contain no more than 3 g of fat.
Da ohranite svojo dnevno ciljno vrednost maščob, prigrizek ne sme vsebovati več kot 3 g maščob.
To stimulate active immunity against babesiosis caused by Babesia canis.
Vzbujanje aktivne imunosti proti babeziozi, ki jo povzroča Babesia canis
To stimulate active immunity against Bluetongue Virus, serotype 1 in sheep.
Za stimulacijo aktivne imunosti proti virusu modrega jezika, serotip 1, pri ovcah.
To stimulate active immunity against bluetongue virus, serotypes 1 and 8 in cattle.
Za stimulacijo aktivne imunosti proti virusu modrega jezika, serotipa 1 in 8, pri govedu.
To stimulate active immunity against bluetongue virus, serotypes 1 and 8 in sheep.
Za stimulacijo aktivne imunosti proti virusu modrega jezika, serotipa 1 in 8, pri ovcah.
To stimulate active immunity against coccidiosis caused by Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella.
Za stimulacijo aktivne imunosti proti kokcidozi, ki jo povzročijo Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix in Eimeria tenella.
To stimulate active immunity against Equine influenza ATC-vet code: QI05AA01
Za vzbujanje aktivne imunosti proti influenci konj Oznaka ATC-vet: QI05AA01
To stimulate active immunity against tetanus.
Za vzbujanje aktivne imunosti proti tetanusu
To stimulate active immunity in cattle from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia*.
Vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika pri govedu od starosti 6 tednov, da zmanjšamo viremijo
To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia*.
Vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika pri ovcah od starosti 1 meseca, da preprečimo viremijo*.
To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia*.
Vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika pri ovcah od starosti 1 meseca, da preprečimo viremijo*..
To stimulate active immunity of cattle, sheep and pigs against purified, inactivated foot-and-mouth disease virus strain antigens related to those contained in the vaccine.
Stimulacija aktivne imunosti proti prečiščenim, inaktiviranim antigenom virusa slinavke in parkljevke pri govedu, ovcah in prašičih (sorodnim antigenom z antigeni v cepivu).
To stimulate immunity against myxoma virus and rabbit haemorrhagic disease virus.
Za stimuliranje imunosti proti miksoma virusu in proti virusu hemoragične bolezni kuncev.
To stop taking Trobalt, it is important that the dose is reduced gradually, over at least 3 weeks.
Pri prenehanju jemanja zdravila Trobalt je pomembno odmerek zmanjševati postopoma, v teku vsaj 3 tednov.
To stop the medicine, your doctor will slowly reduce your Intuniv dose to minimise any side effects.
Zdravnik vam bo ukinil zdravljenje z zdravilom Intuniv tako, da vam bo počasi zmanjševal odmerek zdravila, da se bodo morebitni neželeni učinki kar najbolj zmanjšali.
To study the safety of Biograstim, two further studies were carried out in patients with lung cancer and with non-Hodgkin’s lymphoma.
Za preučitev varnosti zdravila Biograstim sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
To study the safety of Filgrastim ratiopharm, two further studies were carried out in patients with lung cancer and with non-Hodgkin’s lymphoma.
Za preučitev varnosti zdravila Filgrastim ratiopharm sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
To study the safety of Omnitrope, another 51 children have also received the medicine for up to a year.
Da bi preučili varnost zdravila Omnitrope, je zdravilo prejemalo še drugih 51 otrok v trajanju do enega leta.
To study the safety of Ratiograstim, two further studies were carried out in patients with lung cancer and with non-Hodgkin’s lymphoma.
Za proučitev varnosti zdravila Ratiograstim sta bili izvedeni še dve študiji pri bolnikih s pljučnim rakom in z neHodgkinovim limfomom.
To study the safety of Tevagrastim, two further studies were carried out in patients with lung cancer and with non-Hodgkin’s lymphoma.
Za preučitev varnosti zdravila Tevagrastim sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
To submit an updated analysis of overall survival for study CNTO328MCD2001
Vložiti posodobljeno analizo celokupnega preživetja za študijo CNTO328MCD2001
To submit an updated analysis of overall survival for study CNTO328MCD2002
Vložiti posodobljeno analizo celokupnega preživetja za študijo CNTO328MCD2002
To submit pre-specified, exploratory genetic (including NRAS, KRAS, BRAF and PIK3CA) and non-genetic (ANG-2, IL-6, IL-8, P1GF, VEGFR-1, TIE1, VEGF-A, VEGF-C, VEGF-D, VEGF-A-121, BMP-7, VWF, M-CSF, SDF-1) appropriate biomarker analyses from study 15983 (randomised, double-blind, placebo-controlled phase-III study of adjuvant regorafenib versus placebo for patients with stage IV colorectal cancer after curative treatment of liver metastases).
Predložiti vnaprej določeno, raziskovalno genetsko (vključno NRAS, KRAS, BRAF in PIK3CA) in negenetsko (ANG-2, IL-6, IL-8, P1GF, VEGFR-1, TIE1, VEGF-A, VEGF-C, VEGF-D, VEGF-A-121, BMP-7, VWF, M-CSF, SDF-1) ustrezno analizo biokemičnih označevalcev iz študije 15983 (randomizirana, dvojno slepa, s placebom nadzorovana študija III. faze adjuvantnega zdravljenja z regorafenibom v primerjavi s placebom za bolnike v stadiju IV kolorektalnega raka po zdravljenju metastaz v jetrih).
To submit results of biomarker analyses from the Vectibix clinical programme including Study 20080763 (according to Supplementary Statistical Analysis Plan dated 20 September 2013), Study 20070820 and Study 20060447.
Predložiti rezultate analize bioloških označevalcev iz kliničnega programa zdravila Vectibix, vključno s študijo 20080763 (v skladu z načrtom dodatne statistične analize z datumom 20. september 2013), študije 20070820 in študije 20060447.
To submit the results from study P-11, a randomised, double-blind trial evaluating Provenge versus placebo in patients with non-metastatic prostate cancer who experience PSA elevation following radical prostatectomy
Da predloži rezultate študije P-11, randomiziranega, dvojno slepega preskušanja za oceno zdravila Provenge v primerjavi s placebom pri bolnikih z ne- metastatskim rakom prostate, pri katerih je prišlo po radikalni prostatektomiji do zvišanih ravni PSA
To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Adrovance’s ability to increase vitamin D levels.
V podporo uporabi kombinacije alendronske kisline in vitamina D3 v isti tableti in za pridobitev dokazov, da zdravilo Adrovance lahko poveča ravni vitamina D, je družba izvedla študijo s 717 bolniki z osteoporozo, ki je vključevala 682 žensk, ki so že prestale menopavzo.
To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Vantavo’s ability to increase vitamin D levels.
V podporo uporabi kombinacije alendronske kisline in vitamina D3 v isti tableti in za pridobitev dokazov, da zdravilo Vantavo lahko poveča ravni vitamina D, je družba izvedla študijo s 717 bolniki z osteoporozo, ki je vključevala 682 žensk, pri katerih se je že pojavila menopavza.
To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Xarelto for treatment of DVT/PE is available (see section 6.5).
Za lažji prehod z odmerjanja po 15 mg na 20 mg po 21. dnevu je za prve 4 tedne na voljo začetno pakiranje zdravila Xarelto za zdravljenje GVT/PE (glejte poglavje 6.5).
To support the use of Ilaris in AOSD, the company submitted further analyses of the data from the SIJA studies and data from the published literature comparing the disease processes of AOSD and SIJA.
Družba je v podporo uporabi zdravila Ilaris pri Stillovi bolezni, ki se začne v odrasli dobi, predložila dodatne analize podatkov iz študij sistemskega juvenilnega idiopatskega artritisa in podatkov iz objavljene literature, v kateri so primerjali bolezenske procese med tema dvema obolenjema.
To support the use of Vedrop, the company presented information from the scientific literature, including the results of three studies in a total of 92 children and adolescents with chronic cholestasis who were given tocofersolan for about two years.
Družba je v podporo uporabi zdravila Vedrop predstavila podatke iz znanstvene literature, vključno z izidi treh študij pri skupno 92 otrocih in mladostnikih s kronično holestazo, ki so približno dve leti prejemali tokofersolan.
to suppress the immune system
za zaviranje imunskega sistema
To take a dose, the patient places a capsule into the inhaler and breathes in through the mouth the powder contained in the capsule.
Da vzame odmerek, bolnik položi kapsulo v inhalator in skozi usta vdihne prašek, ki ga vsebuje kapsula.
To take a dose, the patient places a capsule into the inhaler and breathes the powder in through the mouth.
Da vzame odmerek, bolnik položi kapsulo v inhalator in skozi usta vdihne prašek.